AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25525051
Drug: Standard-dose (SD)
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose (SD) inactivated influenza vaccine (IIV)
Trial: 15504128
Drug: Terbinafine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine treatment (62.5 mg/day for <20 kg, 125 mg/day for 20-40 kg, 250 mg/day for >40 kg)
Trial: 11223322
Drug: High-dose acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acyclovir
Trial: 8279252
Drug: Epidural bolus
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bolus injection of 4 mg morphine in 2 ml volume (Group I)
Trial: 8279252
Drug: Epidural bolus
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bolus injection of 4 mg morphine in 10 ml volume (Group II)
Trial: 8279252
Drug: Epidural bolus
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bolus injection of 4 mg morphine in 20 ml volume (Group III)
Trial: 26786149
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin at 0.07 IU/kg
Trial: 20394040
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg twice daily
Trial: 20394040
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg initially and then 75 mg once daily
Trial: 16311295
Drug: Mild ovarian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild ovarian stimulation with GnRH antagonist co‐treatment and single embryo transfer (SET)
Trial: 16311295
Drug: Conventional GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional GnRH agonist long protocol ovarian stimulation with double embryo transfer (DET)
Trial: 9546928
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg three times daily
Trial: 9546928
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg three times daily (after excluding patients on potassium-losing diuretics)
Trial: 9546928
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after excluding patients on potassium-losing diuretics)
Trial: 1449116
Drug: Infusional 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusional 5-fluorouracil (5-FU) at 350 mg/m2 per day for 2 weeks with a 2-week rest period on a monthly basis
Trial: 1449116
Drug: Bolus 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus 5-fluorouracil (5-FU) at 400-450 mg/m2 for 5 days every 28 days
Trial: 2931840
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg twice a day)
Trial: 2931840
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg twice a day)
Trial: 22075320
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system (RAS) inhibitors
Trial: 29808753
Drug: No RAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No RAS inhibitors (Control)
Trial: 26841258
Drug: Teriparatide (TPTD)
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide (TPTD) 20 μg/day (s.c. injection)
Trial: 26841258
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid (ZOL) 5 mg/year (i.v. infusion)
Trial: 23017527
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg mirodenafil once daily
Trial: 2065926
Drug: CCK‐8 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK‐8 (20 pmol.kg‐1.h‐1) after saline meal (0.154 mol/L)
Trial: 6807248
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sublingual nifedipine (N)
Trial: 6807248
Drug: 1 mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/Kg intravenous acebutolol (A)
Trial: 6807248
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sublingual nifedipine (N) and 1 mg/Kg intravenous acebutolol (A)
Trial: 27677865
Drug: Grass pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass pollen nasal spray
Trial: 20816042
Drug: Armodafinil 200
RxNorm normalized name: armodafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 200 mg
Trial: 19909829
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate (2.5 mg daily)
Trial: 19084450
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate (20 mg intermittently)
Trial: 31693129
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate
Trial: 12587688
Drug: Artichoke leaf
RxNorm normalized name: artichoke leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artichoke leaf extract (ALE) 320 mg daily
Trial: 12587688
Drug: Artichoke leaf
RxNorm normalized name: artichoke leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artichoke leaf extract (ALE) 640 mg daily
Trial: 8287869
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg trimetazidine as an intravenous (i.v.) bolus followed by an infusion of trimetazidine at 60 mg.24 h‐1 for 48 h (n = 69)
Trial: 3788761
Drug: Mexiletine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (5 to 10 mg/min until >= 95% VPD suppression or total 450 mg, average loading dose 4.4 mg/kg, infusion rate 0.1 mg/kg/min)
Trial: 3788761
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg/kg over 3 minutes, with a second bolus if >= 95% suppression not achieved after 10 minutes)
Trial: 12597674
Drug: Progressive Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive Muscle Relaxation (PMR) training once a week for 4 weeks, practiced at home daily.
Trial: 10334425
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg q.d.)
Trial: 1721246
Drug: Bradykinin (BK)
RxNorm normalized name: dimethicone
DrugBank: Bradykinin (DB12126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bradykinin (BK) after withdrawal of ACE inhibitors
Trial: 30650480
Drug: Raw rhubarbs
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raw rhubarbs by intranasal jejuna injection, 100 mL each time, twice per day for 3-7 days
Trial: 24918563
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment gel
Trial: 23092876
Drug: Autologous costimulated
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous costimulated T-cell product administered on day 2
Trial: 23092876
Drug: T cells
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cells administered on day 90
Trial: 14647963
Drug: Amisulpride (50‐1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (50‐1200 mg/day)
Trial: 14647963
Drug: Amisulpride (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (mean daily doses below 400 mg/day)
Trial: 11589262
Drug: Cerivastatin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.1 mg to 0.4 mg
Trial: 11589262
Drug: Branded Pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded Pravastatin 10 mg to 40 mg
Trial: 9700516
Drug: Methylphenidate (M
RxNorm normalized name: METHYLPHENIDATE (MALLINCK) 27MG SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (M = 26.92 mg/day = 0.78 mg/kg/day)
Trial: 22305
Drug: Aspirin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (600 mg in 1 dl of isotonic saline)
Trial: 28045625
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy after 2 to 4 weeks of neoadjuvant aromatase inhibitor therapy (anastrozole, exemestane, or letrozole)
Trial: 28045625
Drug: Neoadjuvant aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant aromatase inhibitor therapy
Trial: 20707872
Drug: Dental health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental health program including fluoride varnish applied twice per year for 2 years, advocacy for water consumption and daily tooth cleaning with toothpaste, community dental health promotion, and training for primary health care workers in preventive dental care.
Trial: 19539184
Drug: Oral protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral protein supplementation during hemodialysis and peritoneal dialysis
Trial: 19539184
Drug: Oral protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral protein supplementation
Trial: 19539184
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (protein supplementation and control)
Trial: 15327558
Drug: HP cream
RxNorm normalized name: capsaicin Topical Cream [Capzasin-HP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP cream and adapalene 0.1% gel (group HP + A)
Trial: 15327558
Drug: BP cream
RxNorm normalized name: Oral Cream
DrugBank: Cyclomethicone 5 (DB11244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP cream and adapalene 0.1% gel (group BP + A)
Trial: 11009278
Drug: Enoxaparin low
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin low molecular weight heparin
Trial: 9015035
Drug: Intramuscular dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular dexamethasone (6 mg)
Trial: 9015035
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone (8 mg)
Trial: 3526143
Drug: Ganglioside therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganglioside therapy (Cronassial, 40 mg daily)
Trial: 21074334
Drug: Image-guided radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Image-guided radiation therapy (IGRT) using intraprostatic fiducials and Varian's Offline Review image analysis package.
Trial: 3213064
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy for 2 weeks
Trial: 23901675
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy for 4 weeks
Trial: 3213064
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Acupuncture and Physical Therapy)
Trial: 30371925
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 mg orally)
Trial: 30371925
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 µg/kg IV bolus, followed by 0.5 µg/kg/h infusion)
Trial: 30371925
Drug: Pregabalin and
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin and Dexmedetomidine (combined treatment)
Trial: 21884017
Drug: etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 60 or 90 mg daily
Trial: 21884017
Drug: diclofenac 150
RxNorm normalized name: diclofenac sodium 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 150 mg daily
Trial: 20099399
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor strategy
Trial: 9737815
Drug: Oral eprosartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral eprosartan (300 mg) under fasting conditions
Trial: 9737815
Drug: Oral eprosartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral eprosartan (300 mg) following a high-fat breakfast
Trial: 9737815
Drug: Intravenous eprosartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous eprosartan (20 mg)
Trial: 8296748
Drug: Betaxolol 20
RxNorm normalized name: betaxolol 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 20 mg every day
Trial: 29136037
Drug: IV VRC01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV VRC01 (40 mg/kg loading dose followed by five 20 mg/kg doses every 4 weeks)
Trial: 29136037
Drug: IV VRC01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV VRC01 (30 mg/kg doses every 8 weeks)
Trial: 29136037
Drug: IV VRC01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV VRC01 (10 mg/kg doses every 8 weeks)
Trial: 29136037
Drug: SC VRC01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC VRC01 (5 mg/kg every 2 weeks)
Trial: 21167685
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (WP) formula; 35 kcal/kg/d and 1.2 g of protein/kg/d for 5 days
Trial: 21167685
Drug: Casein formula;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein formula; 35 kcal/kg/d and 1.2 g of protein/kg/d for 5 days
Trial: 17401538
Drug: Reboxetine (RBX)
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (RBX) 4 mg twice a day for 4 days preceded by 2 mg twice a day for 2 days
Trial: 15527198
Drug: Qi-therapy (nine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qi-therapy (nine sessions over two menstrual cycles)
Trial: 11137652
Drug: Ambisome (amphotericin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambisome (amphotericin B lipid complex) at a dose of 15mg/kg body weight infused over 2h as a single dose
Trial: 11137652
Drug: amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amphotericin B deoxycholate at a dose of 1mg/kg body infused for 2h for 20 days
Trial: 15845315
Drug: Standard Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Cognitive Behavioral Therapy (CBT)
Trial: 30611722
Drug: NT-proBNP-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP-guided treatment
Trial: 12825133
Drug: Interferon alpha2b
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha2b + Cyclosporin A (200 mg daily for the first 4 weeks and 100 mg daily for the following 20 weeks)
Trial: 12825133
Drug: Interferon alpha2b
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha2b (monotherapy)
Trial: 362094
Drug: Topical glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glycopyrrolate (0.5% and 1.0%)
Trial: 362094
Drug: Topical scopolamine
RxNorm normalized name: scopolamine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical scopolamine
Trial: 362094
Drug: Commercial topical
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial topical antiperspirants
Trial: 25563737
Drug: Whey protein-enriched
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein-enriched preload beverage (300 ml, 1300 kJ, 45 g)
Trial: 23926573
Drug: JNJ-37822681 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-37822681 (10 mg, 20 mg, or 30 mg, twice daily)
Trial: 23926573
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 mg/d during week 1; 15 mg/d after week 1)
Trial: 23926573
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 weeks followed by 6 weeks of olanzapine, 15 mg/d)
Trial: 11051229
Drug: Liquid preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid preparation of DFMO at daily dose 0.5 gram/m2
Trial: 11051229
Drug: Tablet preparation
RxNorm normalized name: Digitalis preparation Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet preparation of DFMO at daily dose 0.5 gram/m2
Trial: 7693506
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg via metered dose inhaler)
Trial: 28472255
Drug: Intensified antituberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified antituberculosis regimen (15 mg/kg/day rifampicin and 20 mg/kg/day levofloxacin for the first 8 weeks)
Trial: 28472255
Drug: Standard 9-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 9-month antituberculosis regimen (10 mg/kg/day rifampicin)
Trial: 17133774
Drug: Valdecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib (40 mg twice daily on day 1 followed by 40 mg once daily on days 2‐7)
Trial: 12642564
Drug: Self-reported home
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported home safety practices (using smoke alarms, stair gates, syrup of ipecac)
Trial: 3395307
Drug: Synthetic food
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic food colourings (50 mg of tartrazine or carmoisine for 2 weeks each)
Trial: 31339245
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable antipsychotics (LAI AP)
Trial: 6345478
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum granules, 15 g/d for 3 months
Trial: 26150193
Drug: First-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation drug-eluting stent
Trial: 21928127
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg MgSO(4) plus 15 mg bupivacaine 0.5%
Trial: 21928127
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg bupivacaine 0.5% with 0.2 ml normal saline (control group)
Trial: 17024872
Drug: Tandem autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem autologous transplants followed by maintenance therapy
Trial: 17024872
Drug: Sequential autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential autologous transplants followed by nonmyeloablative allotransplants
Trial: 17024872
Drug: Induction and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction and/or consolidation treatments
Trial: 15022177
Drug: Harpagophytum extracts
RxNorm normalized name: Harpagophytum procumbens whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harpagophytum extracts with 50-60 mg harpagoside daily
Trial: 15022177
Drug: Proprietary ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proprietary ethanol extract with lower harpagoside dosage
Trial: 10893344
Drug: 1 mU
RxNorm normalized name: benzocaine/cetalkonium 5-1 MUCOUS MEM TROCHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mU x kg(‐1) x min(‐1) insulin infusion for 180 min
Trial: 10893344
Drug: 5 mU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mU x kg(‐1) x min(‐1) insulin infusion for 180 min
Trial: 2252045
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (325 mg on alternate days)
Trial: 6090014
Drug: Doxorubicin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (40 mg/m2 iv every 3 weeks) and Mitomycin (12 mg/m2 iv every 6 weeks)
Trial: 6090014
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m2 iv every 3 weeks X 3, then every 6 weeks) and Etoposide (80 mg/m2 iv on Days 1‐3 every 3 weeks X 3, then every 6 weeks)
Trial: 22410021
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg per hr after an induction bolus of 2 mg/kg)
Trial: 22410021
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (midazolam 0.2 mg/kg for induction without intravenous anesthetic infusion for maintenance)